Literature DB >> 30762607

Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults.

Alvaro Cobo-Calvo1,2, Sandra Vukusic1,2,3, Romain Marignier1,2,3.   

Abstract

PURPOSE OF REVIEW: The clinical interest for auto-antibodies against myelin oligodendrocyte glycoprotein (MOG) has recently reemerged, with the use of more specific detection methods. Large national cohorts have allowed characterizing a more precise clinical spectrum delineated by the presence of human MOG-antibodies. RECENT
FINDINGS: In adults with MOG-antibodies, optic neuritis is the most frequent clinical presentation, with features different from multiple sclerosis (MS), including bilateral involvement and predilection for the anterior part of the optic nerve. Myelitis and brainstem syndrome are also frequent, and may clinically mimic neuromyelitis optica spectrum disorders (NMOSD). Despite the frequently severe clinical presentation, most of patients recover quickly after steroids initiation. Other less typical presentations include encephalitis with seizures, cranial nerve involvement, and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids-like. Although the majority of adult patients follow a relapsing course, long-term prognosis differs from aquaporin-4-antibodies NMOSD, with only a small proportion of patients with a poor outcome.
SUMMARY: MOG-antibodies-associated disease is a new entity in the spectrum of inflammatory demyelinating diseases, distinct from both MS and NMOSD. There is a crucial need to identify factors associated to the risk of relapse or poor outcome, to seek patient subgroups in which immunoactive treatments could be beneficial.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30762607     DOI: 10.1097/WCO.0000000000000681

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  7 in total

1.  Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Authors:  Fiona Tea; Joseph A Lopez; Sudarshini Ramanathan; Vera Merheb; Fiona X Z Lee; Alicia Zou; Deepti Pilli; Ellis Patrick; Anneke van der Walt; Mastura Monif; Esther M Tantsis; Eppie M Yiu; Steve Vucic; Andrew P D Henderson; Anthony Fok; Clare L Fraser; Jeanette Lechner-Scott; Stephen W Reddel; Simon Broadley; Michael H Barnett; David A Brown; Jan D Lunemann; Russell C Dale; Fabienne Brilot
Journal:  Acta Neuropathol Commun       Date:  2019-09-03       Impact factor: 7.801

Review 2.  Biomarkers in Rare Demyelinating Disease of the Central Nervous System.

Authors:  Marina Boziki; Styliani-Aggeliki Sintila; Panagiotis Ioannidis; Nikolaos Grigoriadis
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

3.  Is there a correlation between MOG-associated disorder and SARS-CoV-2 infection?

Authors:  Sara Mariotto; Sara Carta; Alessandro Dinoto; Giuseppe Lippi; Gian Luca Salvagno; Laura Masin; Daniela Alberti; Romain Marignier; Sergio Ferrari
Journal:  Eur J Neurol       Date:  2022-03-14       Impact factor: 6.089

4.  The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review.

Authors:  Yun-Feng Wang; Xue-Wu Liu; Jian-Ming Lin; Ji-Ye Liang; Xiu-He Zhao; Sheng-Jun Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

5.  Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry.

Authors:  Fiona Tea; Deepti Pilli; Sudarshini Ramanathan; Joseph A Lopez; Vera Merheb; Fiona X Z Lee; Alicia Zou; Ganesha Liyanage; Chelsea B Bassett; Selina Thomsen; Stephen W Reddel; Michael H Barnett; David A Brown; Russell C Dale; Fabienne Brilot
Journal:  Front Immunol       Date:  2020-02-06       Impact factor: 7.561

6.  Myelin Oligodendrocyte Glycoprotein Antibody Associated Cerebral Cortical Encephalitis: Case Reports and Review of Literature.

Authors:  Hang Shu; Manqiu Ding; Pei Shang; Jia Song; Yue Lang; Li Cui
Journal:  Front Hum Neurosci       Date:  2022-01-03       Impact factor: 3.169

7.  GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder.

Authors:  Fumitaka Shimizu; Ryo Ogawa; Yoichi Mizukami; Kenji Watanabe; Kanako Hara; Chihiro Kadono; Toshiyuki Takahashi; Tatsuro Misu; Yukio Takeshita; Yasuteru Sano; Miwako Fujisawa; Toshihiko Maeda; Ichiro Nakashima; Kazuo Fujihara; Takashi Kanda
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.